Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
24
07
2020
accepted:
11
11
2020
revised:
13
10
2020
pubmed:
30
11
2020
medline:
10
7
2021
entrez:
29
11
2020
Statut:
ppublish
Résumé
The association of Cyclosporine A (CsA) and mycophenolate mofetil (MMF) has increased in the setting of reduced intensity conditioning (RIC). Nevertheless, the use of CsA or CsA+MMF has not been reported in a large and uniform cohort. We analyzed 497 patients with acute myeloid leukemia in complete remission (CR) who underwent matched unrelated donor (MUD) hematopoietic stem cell transplantation (HSCT). All patients received a fludarabine busulfan RIC regimen and anti-thymocyte globulin (ATG) with either CsA alone or in combination with MMF. The cumulative incidence (CI) of grade II-IV acute GvHD was 27% (95% CI 21-33%) for CsA and 33% (95% CI 27-38%) for CsA+MMF (p = 0.25). The 2-year CI of chronic GvHD was 38% (95% CI 31-45%) and 33% (95% CI 28-39%) for the CsA and the CsA+MMF group, respectively (p = 0.26). On multivariate analysis, no statistically significant differences with respect to relapse incidence (RI), non-relapse mortality (NRM), leukemia-free survival (LFS), overall survival (OS), acute and chronic GvHD were found between the two groups, also when conducting a subgroup analysis in peripheral blood stem cells (PBSC) recipients. Our results support the importance of randomized trial to identify patients who could benefit from the addition of MMF in MUD HSCT.
Identifiants
pubmed: 33249424
doi: 10.1038/s41409-020-01155-z
pii: 10.1038/s41409-020-01155-z
doi:
Substances chimiques
Calcineurin Inhibitors
0
Mycophenolic Acid
HU9DX48N0T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1077-1085Références
Powles RL, Clink HM, Spence D, Morgenstern G, Watson JG, Selby PJ, et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet Lond Engl. 1980;1:327–9.
doi: 10.1016/S0140-6736(80)90881-8
Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2012;47:1459–64.
doi: 10.1038/bmt.2012.45
Ram R, Herscovici C, Dahan D, Israeli M, Dreyer J, Peck A, et al. Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil. Leuk Res. 2014;38:913–7.
doi: 10.1016/j.leukres.2014.05.020
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N. Engl J Med. 1986;314:729–35.
doi: 10.1056/NEJM198603203141201
Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transpl. 2004;34:621–5.
doi: 10.1038/sj.bmt.1704647
Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transpl. 2005;35:1089–93.
doi: 10.1038/sj.bmt.1704956
Piñana JL, Valcárcel D, Fernández-Avilés F, Martino R, Rovira M, Barba P, et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transpl. 2010;45:1449–56.
doi: 10.1038/bmt.2009.362
Kiehl MG, Schäfer-Eckart K, Kröger M, Bornhäuser M, Basara N, Blau IW, et al. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. Transpl Proc. 2002;34:2922–4.
doi: 10.1016/S0041-1345(02)03489-9
Yerushalmi R, Shem-Tov N, Danylesko I, Shouval R, Nagler A, Shimoni A. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors. Am J Hematol. 2017;92:259–68.
doi: 10.1002/ajh.24631
Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, et al. Comparative analysis of calcineurin inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of graft-versus-host disease after reduced-intensity conditioning allogeneic transplantation. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2019;25:73–85.
doi: 10.1016/j.bbmt.2018.08.018
Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! Bone Marrow Transpl. 2014;49:599–606.
doi: 10.1038/bmt.2013.226
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.
doi: 10.1182/blood-2009-11-254441
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2005;11:945–56.
doi: 10.1016/j.bbmt.2005.09.004
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295–304.
doi: 10.1097/00007890-197410000-00001
Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610–1.
doi: 10.1038/bmt.2015.305
Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489–500.
doi: 10.1002/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#
Hougaard P. Frailty models for survival data. Lifetime Data Anal. 1995;1:255–73.
doi: 10.1007/BF00985760
Mohty M, de Lavallade H, Faucher C, Bilger K, Vey N, Stoppa A-M, et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transpl. 2004;34:527–30.
doi: 10.1038/sj.bmt.1704640
Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, et al. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors. Bone Marrow Transpl. 2010;45:786–8.
doi: 10.1038/bmt.2009.218
Rodriguez R, Nademanee A, Palmer JM, Parker P, Nakamura R, Snyder D, et al. Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD. Bone Marrow Transpl. 2010;45:205–7.
doi: 10.1038/bmt.2009.112
Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, et al. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019;6:e409–18.
doi: 10.1016/S2352-3026(19)30088-2
Vogelsang GB, Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transpl. 2001;27:1255–62.
doi: 10.1038/sj.bmt.1703076
Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N. Engl J Med. 2016;374:43–53.
doi: 10.1056/NEJMoa1506002
Rubio MT, Labopin M, Blaise D, Socié G, Contreras RR, Chevallier P, et al. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2015;100:683–9.
doi: 10.3324/haematol.2014.119339
Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013;122:3359–64.
doi: 10.1182/blood-2013-05-499830
Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127:2427–38.
doi: 10.1182/blood-2015-11-679639
Jacobson PA, Huang J, Wu J, Kim M, Logan B, Alousi A, et al. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2010;16:421–9.
doi: 10.1016/j.bbmt.2009.11.010
Nishikawa S, Okamura A, Yamamori M, Minagawa K, Kawamori Y, Kawano Y, et al. Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease. Transpl Proc. 2009;41:3873–6.
doi: 10.1016/j.transproceed.2009.06.231
Barkholt L, Remberger M, Bodegård H, Ringdén O, Böttiger Y. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transpl. 2007;40:683–9.
doi: 10.1038/sj.bmt.1705788
Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Delaunay J, et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2010;16:28–34.
doi: 10.1016/j.bbmt.2009.08.010